Following combination treatment with Lapatinib and the anthracycline Doxorubicin in an MMTV-neu mice HER2-positive breast cancer model, CD8+ T-cells secreting IFN-γ contributed to the anti-tumor effects of these drugs. The gene discussed is CD8A; the disease is breast cancer.